Alejandro Gonzalez Campos, MD
Endocrinology, Diabetes & Metabolism · Edinburg, TXNPI 1508130543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,375 of the $185,311 with a category attached, or 89.2%. Lilly USA, LLC accounts for 96.0% of it on its own, with 34 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 665 payments — averaging $278.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$178K
- Dexcom, Inc.$2K
- Novo Nordisk$1K
- Ascensia Diabetes Care US Inc.$626
- Corcept Therapeutics$500
- AstraZeneca$467
- plus $3K from 29 others
Across 5 payments — averaging $101,749 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$497K
- Eli Lilly Export S.A. Puerto Rico Branch$12K
What the payments were for
- Speaking & faculty fees$165,37589%
- Travel & lodging$7,5114%
- Food & beverage$12,0807%
- Education$2590%
- Gifts$590%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 362 | $177,950 |
| Dexcom, Inc. | 42 | $1,536 |
| Novo Nordisk | 77 | $1,290 |
| Ascensia Diabetes Care US Inc. | 17 | $626 |
| Corcept Therapeutics | 21 | $500 |
| AstraZeneca(2 entities) | 12 | $467 |
| Insulet Corporation | 8 | $369 |
| Amgen(2 entities) | 29 | $349 |
| Abbott | 14 | $308 |
| Mannkind Corporation | 12 | $299 |
| Janssen Products, LP | 2 | $231 |
| Radius Health, Inc. | 19 | $207 |
| Novartis | 7 | $121 |
| Merck | 1 | $114 |
| Boehringer Ingelheim | 5 | $113 |
| Cequr Corporation | 3 | $99 |
| Philips North America LLC | 1 | $91 |
| Bayer | 4 | $66 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Amryt Pharma Holdings Ltd | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $51 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Tandem Diabetes Care, Inc. | 3 | $46 |
| Senseonics, Incorporated | 1 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Echosens North America, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,311 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 499 | $695,608 |
| OzempicSemaglutide | 301 | $400,923 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 63 | $146,985 |
| JardianceEmpagliflozin | 109 | $129,850 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 102 | $115,946 |
| FarxigaDapagliflozin Propanediol | 97 | $96,647 |
| TrulicityDulaglutide | 40 | $62,845 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $60,498 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $49,148 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $46,231 |
| SynjardyEmpagliflozin/Metformin Hcl | 34 | $37,825 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $33,106 |
| ProliaDenosumab | 19 | $31,200 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $28,469 |
| RybelsusSemaglutide | 20 | $27,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $177,950 | $758,454539 claims |
| Novo NordiskOzempic, Rybelsus | $1,290 | $428,317321 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $113 | $304,817268 claims |
| AmgenEvenity (2 Syringes), Prolia | $349 | $178,18582 claims |
| AstraZenecaFarxiga | $467 | $96,64797 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Edinburg
- Eduardo LunaEdinburg$1.3M
- Surya MulukutlaEdinburg$195K
- Jose Llinas CepedaEdinburg$136K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.